A recent survey revealed significant variability in treatment decisions for pediatric MOGAD, highlighting gaps in knowledge and the potential need for improved clinical guidelines.

Andrew Varga, MD, PhD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, provided comment on a featured debate at the 2025 SLEEP Annual Meeting exploring the evolving science behind glymphatic clearance and its potential link to Alzheimer disease.

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

Recent findings suggest that laser interstitial thermal therapy could offer patients with drug-resistant mesial temporal lobe epilepsy a minimally invasive and safe therapeutic option.

A study links high ultraprocessed food consumption to increased risks of nonmotor Parkinson's disease symptoms, highlighting potential dietary impacts on neurodegeneration.

Nester Tomycz, MD, director of neurosurgical pain division at Allegheny General Hospital, discussed emerging neurosurgerical approaches for chronic pain, with a focus on neuromodulation, patient selection, and non-opioid treatment pathways.

Panelists discuss the clinical presentation, diagnostic approaches, and treatment considerations for narcolepsy, offering practical insights to guide health care professionals new to its diagnosis and management.

The professor and chair of neuroscience at UT Southwestern Medical Center offered an overview on his keynote lecture presented at AHS 2025 on the circadian clock in relation to headache.

A recent study highlighted key unmet needs and barriers that may lead to preventable nursing home placements among Black, Hispanic/Latino, and White patients living with dementia.

Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.

Panelists discuss the clinical presentation, diagnostic approaches, and treatment considerations for narcolepsy, offering practical insights to guide health care professionals new to its diagnosis and management.

A groundbreaking trial reveals that subthalamic deep brain stimulation effectively treats isolated dystonia, showing significant long-term motor and mental health improvements.

Patients using intranasal zavegepant for acute migraines report significant pain relief and improved daily functioning, highlighting its real-world effectiveness.

Takeda reveals promising phase 3 results for oveporexton, a potential breakthrough treatment for narcolepsy type 1, targeting excessive daytime sleepiness.

Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits.

Here's some of what is coming soon to NeurologyLive® this week.

INmune Bio's XPro shows promise as a treatment for patients with Alzheimer disease, revealing cognitive benefits despite mixed phase 2 trial results.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Alzheimer's Association International Conference.

A recent study reveals a decline in multiple sclerosis progression rates, highlighting the impact of improved treatments and the need for ongoing innovation in care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.

The investigational oral orexin receptor 2-selective agonist oveporexton is designed to restore orexin signaling to address the underlying orexin deficiency that is caused by narcolepsy type 1.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joyce Lee-Iannotti, MD, PhD. [LISTEN TIME: 17 minutes]

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.

West Nile virus poses increasing neurologic risks in the US, with new strains emerging and significant health implications for vulnerable populations.